U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C9H10N2O
Molecular Weight 162.1885
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMINOREX

SMILES

NC1=NCC(O1)C2=CC=CC=C2

InChI

InChIKey=SYAKTDIEAPMBAL-UHFFFAOYSA-N
InChI=1S/C9H10N2O/c10-9-11-6-8(12-9)7-4-2-1-3-5-7/h1-5,8H,6H2,(H2,10,11)

HIDE SMILES / InChI
Molecular Formula C9H10N2O
Molecular Weight 162.1885
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Aminorex is an anorectic stimulant drug. Aminorex inhibits norepinephrine and dopamine transporters with IC50 of 0.33 and 0.85 uM. It was briefly available as an appetite suppressant in the 1960s in Switzerland, Germany, and Austria, but was found to cause pronounced vasoconstriction in the pulmonary vasculature, and was withdrawn from the market in 1972 due to several cases of fatal and life-threatening pulmonary hypertension. In the USA aminorex is an illegal schedule I drug.

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
Pulmonary hypertension associated with use of phentermine.
2010-11
Levamisole: a dangerous new cocaine adulterant.
2010-09
The serotonin hypothesis of pulmonary hypertension revisited.
2010
Aminorex and rexamino as metabolites of levamisole in the horse.
2009-04-06
The formation of aminorex in racehorses following levamisole administration. A quantitative and chiral analysis following synthetic aminorex or levamisole administration vs. aminorex-positive samples from the field: a preliminary report.
2009-04
Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns.
2009-01
Pulmonary hypertension: therapeutic targets within the serotonin system.
2008-10
Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice.
2008-06-03
Pharmacokinetics and effects of aminorex in horses.
2008-05
Effects on weight reduction and safety of short-term phentermine administration in Korean obese people.
2006-10-31
Temporal trends and drug exposures in pulmonary hypertension: an American experience.
2006-09
Safety of drug therapies used for weight loss and treatment of obesity.
2006
A century of pulmonary hemodynamics.
2004-07-15
Primary pulmonary arterial hypertension: a look back.
2004-06-16
Noradrenergic modulation of ephedrine-induced hypophagia.
2003-04
Therapeutic and adverse actions of serotonin transporter substrates.
2002-07
Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine.
2002-06-07
Appetite suppressants as agonist substitution therapies for stimulant dependence.
2002-06
[Pulmonary hypertension and obesity].
2002-04
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis.
2002
Risk factors for pulmonary arterial hypertension.
2001-09
Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5.
2001-09
[Drug induced pulmonary hypertension].
2001-06
Anorectic drugs and pulmonary hypertension from the bedside to the bench.
2001-04
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
2001-01
[Obesity: principles of drug therapy].
2000-08
[Anorectics and pulmonary hypertension].
2000-02-16
[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].
1998-12-01
Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension.
1998-12
Two different drug-induced pulmonary complications in a patient suffering from rheumatoid arthritis.
1998-05
Aminorex, dexfenfluramine, and primary pulmonary hypertension.
1998-04
Pulmonary hypertension and dexfenfluramine.
1995
[A case of chronic pulmonary hypertension after fenfluramine intake].
1982-11-26
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:16:35 GMT 2025
Edited
by admin
on Mon Mar 31 18:16:35 GMT 2025
Record UNII
2SH16612I9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
APIQUEL
Preferred Name English
AMINOREX
HSDB   INN   MART.   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
AMINOREX [MI]
Common Name English
aminorex [INN]
Common Name English
(±)-2-AMINO-5-PHENYL-2-OXAZOLINE
Systematic Name English
2-Amino-5-phenyl-2-oxazoline
Systematic Name English
MCN-742
Code English
AMINOREX [HSDB]
Common Name English
NSC-66952
Code English
2-OXAZOLAMINE, 4,5-DIHYDRO-5-PHENYL-
Systematic Name English
Aminorex [WHO-DD]
Common Name English
AMINOREX [MART.]
Common Name English
AMINOREX [USAN]
Common Name English
Classification Tree Code System Code
DEA NO. 1585
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
NCI_THESAURUS C29728
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL106258
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
WIKIPEDIA
AMINOREX
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
INN
1652
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
CAS
2207-50-3
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
EVMPD
SUB05448MIG
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
DRUG CENTRAL
175
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
MERCK INDEX
m1742
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY Merck Index
PUBCHEM
16630
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
DRUG BANK
DB01490
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
EPA CompTox
DTXSID00862867
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
NCI_THESAURUS
C72180
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
FDA UNII
2SH16612I9
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
SMS_ID
100000087229
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
MESH
D000635
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
HSDB
7596
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
NSC
66952
Created by admin on Mon Mar 31 18:16:35 GMT 2025 , Edited by admin on Mon Mar 31 18:16:35 GMT 2025
PRIMARY
Related Record Type Details
Structure of AMINOREX FUMARATE
SALT/SOLVATE -> PARENT
Structure of AMINOREX, (R)-
ENANTIOMER -> RACEMATE
Structure of AMINOREX, (S)-
ENANTIOMER -> RACEMATE
Related Record Type Details
Structure of AMINOREX
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966